Latebreakers: Warnings added for Exjade
Changes have been made to the prescribing information for deferasirox (Exjade, Novartis) following postmarketing reports of acute renal failure and cytopenias, including agranulocytosis, neutropenia, and thrombocytopenia.
Changes have been made to the prescribing information for deferasirox (Exjade, Novartis) following postmarketing reports of acute renal failure and cytopenias, including agranulocytosis, neutropenia, and thrombocytopenia. Fatalities were reported in both groups; however, most occurred in patients with comorbidities and preexisting disorders. According to Novartis, the relationship of these adverse reactions and deaths to deferasirox therapy is uncertain. Deferasirox is indicated for the treatment of chronic iron overload due to blood transfusions (transfusional hemosiderosis) in patients two years of age and older.
Pharmacists Play Unique Role in Advancing Health Equity for Patients With Chronic Disease
December 7th 2023A new study, outlined in a poster at ASHP Midyear 2023, identified 3 key themes associated with the ways in which pharmacists are positioned to advance health equity for patients with chronic diseases.
